Sucampo Pharmaceuticals — Q4 2016 Earnings Presentation
29 slides from Sucampo Pharmaceuticals's earnings presentation, Mar 8, 2017
Slide 1: Fourth Quarter 2016 Corporate Update and Financial Results
March 8, 2017 Fourth Quarter 2016 Corporate Update and Financial Results
Slide 2: Introductions and Forward-Looking Statements
Introductions and Forward - Looking Statements Silvia Taylor, SVP Investor Relations & Corporate Affairs
Slide 3: Agenda
Agenda Introductions and Forward - Looking Statements Silvia Taylor Corporate Update Peter Greenleaf Pipeline Update Peter Kiener , D. Phil Financial Update Andrew Smith Closing Remarks Peter Greenleaf 3
Slide 4: Forward Looking Statement
Forward Looking Statement This presentation contains "forward - looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ
Slide 5: Non-GAAP Metrics
Non - GAAP Metrics This presentation contains three financial metrics (Adjusted Net Income, EBITDA and Adjusted EBITA) that are considered “non - GAAP” financial metrics under applicable Securities and Exchange Commission rules and regulations. These non - GAAP financial metr ics should be considere
Slide 6: Q4 and FY 2016
Q4 and FY 2016 Corporate Update Peter Greenleaf, Chairman and CEO
Slide 7: Continued Financial and Operational Performance
Continued Financial and Operational Performance 4Q REVENUE • Overall revenue grew 32% YoY to $73M • Product sales grew 43% to $42M • Product royalty revenue grew 15% to $26M EARNINGS* * Adjusted figures exclude non - cash , one time items, and items associated with RTU acquisition ** Adjusted EBITDA
Slide 8: Pipeline Progress
Pipeline Progress • Significant changes to pipeline completed • Two key programs remaining: – Life - cycle management of AMITIZA – Phase 3 partnership with CPP in FAP 8
Slide 9: Positioning Sucampo for Mid to Long-Term Growth
Positioning Sucampo for Mid to Long - Term Growth • Significant progress in integration of RTU following late 2015 acquisition – Including manufacturing of AMITIZA and RESCULA • Collaboration and option agreement with CPP completed in 2016 • Settlement and license agreement with Dr. Reddy’s regardin
Slide 10: Strong Balance Sheet
Strong Balance Sheet • Completed a $300M convertible senior notes offering in late 2016 in private placement to qualified institutional buyers • Proceeds used to pay off $250M credit facility • Use of proceeds includes completing additional transactions 10
Slide 11: Strong Q4 2016 U.S. AMITIZA Performance
Strong Q4 2016 U.S. AMITIZA Performance • Takeda’s AMITIZA net sales for royalty calculation purposes – Q4 grew 11% YoY to $114M • Royalty revenue grew 15% YoY to $26M – Driven by price increase in January 2016 and volume • U.S. AMITIZA product sales to Takeda of $13M • Total U.S. revenue of $39M •
Slide 12: Expected AMITIZA U.S. Growth Drivers
Expected AMITIZA U.S. Growth Drivers • Competitive positioning in commercial and Part D payer plans – CVS Caremark preferred formulary • Highly - targeted DTC television campaign in select key markets • Encouraging growth trends for AMITIZA early in 2017 • Takeda took 6% price increase in January of
Slide 13: Japan AMITIZA Performance
Japan AMITIZA Performance • Sucampo Q4 revenue: $26.2M, growth of 46% YoY – Includes $10M milestone related to achievement of certain revenue targets • Excluding milestone payments, Q4 revenue grew 25% YoY • Driven by volume – Increased 41% YoY for the full year of 2016 • Growth drivers: – Strong ma
Slide 14: 2017 Guidance Reiterated
2017 Guidance Reiterated • Total revenue: $220 million to $230 million • Adjusted net income: $80 million to $90 million • Adjusted EPS: $1.35 to $1.50 • Adjusted EBITDA: $145 million to $155 million • Revenue does not include any milestone payments Adjusted net income guidance excludes amortization
Slide 15: Senior Management Transitions
Senior Management Transitions • Andrew Smith transitioning out of CFO role to move back to Europe with family to purse professional opportunities there – Effective March 20 – Will assist with transition • Peter Pfreundschuh , CPA, appointed CFO effective March 20 – Experienced CFO – Immunomedics , C
Slide 16: Pipeline Update
Pipeline Update Peter Kiener , D. Phil, CSO
Slide 17: Pediatric Phase 3 Results with Current Formulation
Pediatric Phase 3 Results with Current Formulation • Phase 3 trial of AMITIZA vs. placebo in children 6 to 17 years of age • Evaluated doses of 12 and 24 mcg over 12 weeks • Primary endpoint of overall spontaneous bowel movement (SBM) response • Did not achieve primary endpoint of overall SBM respon
Slide 18: FDA Feedback
FDA Feedback • FDA to review complement of data from AMITIZA phase 3 pediatric program – Including final long term safety and efficacy data from 9 - month extension • FDA confirmed aggregate data will be sufficient to submit sNDA for pediatric indication • Expect to file sNDA in 2H 2017 • Phase 3 st
Slide 19: Product Pipeline
19 Product Pipeline Sucampo Program Option Program Target First Indication Development Stage (s)NDA / MAA Filing Approval GI/Metabolic/ Inflamation AMITIZA CIC2 Pediatric functional constipation (6 - 17 yrs.) P3 2017 2018 Lubiprostone Sprinkle Formulation CIC2 Pediatric functional constipation 6 mos
Slide 20: Financial Update
Financial Update Andrew Smith, CFO
Slide 21: Q4 Revenue
Q4 Revenue 21 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 Q4 2015 Amitiza US royalty Amitiza US product sales Amitiza Japan product sales Amitiza Japan milestone R&D Revenue Q4 2016 $ Million
Slide 22: Q4 Adjusted Net Income
Q4 Adjusted Net Income 22 0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 Q4 2015 Gross margin Op Ex Acquisition related exp Tax rate Non-operating exp Q4 2016 $ Million
Slide 23: Q4 Adjusted EBITDA
Q4 Adjusted EBITDA 23 0.0 10.0 20.0 30.0 40.0 50.0 Q4 2015 Gross margin Operating expense Exchange loss Q4 2016 $ Million
Slide 24: Key Balance Sheet Items
Key Balance Sheet Items Item As of 12 /31/16 Change As of 12/31/15 Cash, Cash Equivalents and Restricted Cash $198.5M $35.0M $163.5M Notes Payable $290.5M ($38.1M) $252.4M Net Debt $92.0M ($3.1M) $88.9M 24
Slide 25: Closing Remarks
Closing Remarks Peter Greenleaf, Chairman and CEO
Slide 26: 2017 Areas of Focus
2017 Areas of Focus 1. Deliver outstanding financial performance, both top and bottom line 2. Progress pipeline programs 3. Evaluate and execute on additional opportunities for growth 26
Slide 27: Q&A Session
Q&A Session
Slide 28: Reconciliation of GAAP Net Loss to Non-GAAP Net Income
Reconciliation of GAAP Net Loss to Non - GAAP Net Income 28 RECONCILIATION OF GAAP NET LOSS TO NON-GAAP NET INCOME (in thousands, except per share amounts) Three Months Ended Three Months Ended For the Year Ended For the Year Ended December 31, 2016 December 31, 2015 December 31, 2016 December 31, 2
Slide 29: Reconciliation of Income from Operations to Adjusted EBITDA
Reconciliation of Income from Operations to Adjusted EBITDA 29 RECONCILIATION OF INCOME FROM OPERATIONS TO ADJUSTED EBITDA (in thousands, except per share amounts) Three Months Ended Three Months Ended For the Year Ended For the Year Ended December 31, 2016 December 31, 2015 December 31, 2016 Decemb
Sucampo Pharmaceuticals — Q4 2016 Earnings Presentation on 6ix